source
- Neurosterix raises $105M Series B to advance oral M4 schizophrenia drug and adds former Karuna leadersNeurosterix, a spinout from Addex Therapeutics, announced a $105 million Series B financing. The round was led by RTW Investments with participation from GV, Janus Henderson Investors and others. A…
- Scientists release detailed basal ganglia cell map, uncover new neuron linked to schizophreniaScientists from a large international collaboration have created the most detailed map of the basal ganglia, a brain region that coordinates movement and emotion. The effort profiled over 25 millio…